Table of contents

  • Brand Names
  • Chemistry
  • Pharmacologic Category
  • Mechanism of Action
  • Therapeutic Use
  • Pregnancy and Lactation Implications
  • Contraindications
  • Warnings and Precautions
  • Adverse Reactions
  • Caution and personalized dose adjustment in patients with the following genotypes
  • Other genes that may be involved
  • Substrate of
  • Inhibits
  • Drug Interactions
  • Nutrition/Nutraceutical Interactions
  • Dosage
  • Pharmacokinetics and Pharmacodynamics
  • Special Considerations

Brand Names


Austria: Detrusan, Ditropan, Incotrol, Kentera, Oxybutynin; Belgium: Ditropan, Kentera, Oxybutynine; Cyprus: Kentera; Czech Republic: Ditropan, Kentera, Uroxal; Denmark: Kentera; Estonia: Driptane, Kentera; Finland: Cystrin, Kentera, Oxybutynin; France: Ditropan, Driptane, Kentera, Lotreve, Oxybutynine, Zatur; Germany: Cystonorm, Dridase, Kentera, Lyrinel, Oxybugamma, Oxybutin, Oxybuton, Oxybutynin, Oxymedin, Ryol, Spasmex Oxybutynin, Spasyt; Greece: Caprilonal, Ditropan, Kentera, Lyrinel, Oxybase; Hungary: Ditropan, Kentera, Uroxal; Ireland: Cystrin, Ditropan, Kentera, Lyrinel, Oxybutynin; Italy: Ditropan, Ossibutinina, Oxibutinina; Latvia: Kentera; Lithuania: Kentera; Luxembourg: Ditropan; Malta: Kentera; Netherlands: Dridase, Kentera, Oxybutynine; Poland: Cystrin, Ditropan, Driptane, Kentera, Uristop, Uroton; Portugal: Ditropan, Kentera, Lyrinel, Oxibutinina; Romania: Driptane, Kentera, Oxybutynin; Slovakia: Ditropan, Eurin, Kentera, Oxybutynin, Uroxal; Spain: Ditropan; Sweden: Ditropan, Kentera, Oxybutynin; UK: Cystrin, Ditropan, Kentera, Lyrinel, Oxybutynin.

North America

Canada: Ditropan, Oxybutyn, Oxybutynin, Oxytrol, Uromax; USA: Ditropan, Gelnique, Oxybutynin, Oxytrol.

Latin America

Argentina: Delak, Ditropan, Oxibutinina, Oxi-Q, Oxitina, Oxyurín, Retebem, Retemicón, Soxsup, Tinaxina, Urequín; Brazil: Incontinol, Oxibutinina, Retemic; Mexico: Inprax, Lyrinel, Nefryl, Tavor-Asofarma.


Japan: Cobapolas, Delaiv, Ditropan, Fandeheede, Halarase, Inobase, Nelous, Orivate, Oxytrol, Palnaxol, Pollakisu, Porabutin, Poratile, Postinin, Urgent.

Drug combinations


Oxybutynin Chloride: C~22~H~31~NO~3~ HCl. Mw: 393.95. (1) Benzeneacetic acid, α-cyclohexyl-α-hydroxy-, 4-(diethylamino)-2-butynyl ester hydrochloride, (±)-; (2) 4-(Diethylamino)-2-butynyl (±)-α-phenylcyclohexaneglycolate hydrochloride. CAS-1508-65-2 (1962).

Pharmacologic Category

Genitourinary Smooth Muscle Relaxants. Urinary Antispasmodic Agent. (ATC-Code: G04BD04).

Mechanism of action

Competitive antagonist of acetylcholine at postganglionic muscarinic receptors. Has direct antispasmodic effect on smooth muscle, also inhibits muscarinic action of acetylcholine on smooth muscle. Does not block effects at skeletal muscle or at autonomic ganglia. Relaxes bladder smooth muscle, thus increasing bladder capacity, decreasing uninhibited contractions, and delaying desire to void, therefore, decreases urgency and frequency of incontinent episodes and voluntary urination. Does not appear to exhibit antinicotinic effects (i.e. block acetylcholine effects at skeletal myoneural junctions or at autonomic ganglia). Racemic mixture of R- and S-isomers. Antimuscarinic activity resides predominantly in R-isomer.

Therapeutic use

Antispasmodic for neurogenic bladder (urgency, frequency, urge incontinence).

Pregnancy and lactiation implications

Teratogenic effects not observed in animals. There are no adequate studies in pregnant women. Use during pregnancy only if clearly needed. Excretion in breast milk unknown (use caution).

Unlabeled use


Hypersensitivity to oxybutynin or any component of the formulation. Untreated glaucoma. Urinary retention. Gastric retention or conditions with severely decreased gastrointestinal motility. Myasthenia gravis. Unstable cardiovascular status in acute hemorrhage.

Warnings and precautions

May cause anticholinergic effects (e.g. agitation, confusion, hallucinations, somnolence). May cause CNS depression. May increase risk of heat prostration. Use with caution in autonomic neuropathy (may exacerbate condition), in heart failure, hypertension, and/or cardiac arrhythmias (may exacerbate condition), in dementia (may aggravate symptoms of disease), and in ulcerative colitis, intestinal atony, gastroesophageal reflux or with medications which may exacerbate esophagitis (e.g. bisphosphonates). May decrease GI motility; in ulcerative colitis, use may increase risk of paralytic ileus or toxic megacolon. Use with caution in hiatal hernia, in treated angle-closure glaucoma (may exacerbate condition; contraindicated with untreated glaucoma), in hepatic impairment (limited experience), in hyperthyroidism (may exacerbate condition), in myasthenia gravis (may exacerbate condition). Use with caution in prostatic hyperplasia and/or urinary stricture (may cause urinary retention), in renal impairment, and in the elderly due to anticholinergic activity (e.g. confusion, constipation, blurred vision, and tachycardia). May contain conducting metal (e.g. aluminum). May suppress wheal and flare reactions to skin test antigens.



Legal Notice
Privacy Policy
Cookie Policy


Phone: +34-981-780505
Email: genomicmedicine@wagem.org
Location: Sta Marta de, C. P. Babío, S/N, 15165 Bergondo, A Coruña

Copyright © 2023 WAGEM

Add to cart